Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

Guanlan Xu,Tiffany D. Grimes,Truman B. Grayson,Junqin Chen,Lance A. Thielen,Hubert M. Tse,Peng Li,Matt Kanke,Tai-Tu Lin,Athena A. Schepmoes,Adam C. Swensen,Vladislav A. Petyuk,Fernando Ovalle,Praveen Sethupathy,Wei-Jun Qian,Anath Shalev
DOI: https://doi.org/10.1038/s41467-022-28826-3
IF: 16.6
2022-03-03
Nature Communications
Abstract:Abstract Currently, no oral medications are available for type 1 diabetes (T1D). While our recent randomized placebo-controlled T1D trial revealed that oral verapamil had short-term beneficial effects, their duration and underlying mechanisms remained elusive. Now, our global T1D serum proteomics analysis identified chromogranin A (CHGA), a T1D-autoantigen, as the top protein altered by verapamil and as a potential therapeutic marker and revealed that verapamil normalizes serum CHGA levels and reverses T1D-induced elevations in circulating proinflammatory T-follicular-helper cell markers. RNA-sequencing further confirmed that verapamil regulates the thioredoxin system and promotes an anti-oxidative, anti-apoptotic and immunomodulatory gene expression profile in human islets. Moreover, continuous use of oral verapamil delayed T1D progression, promoted endogenous beta-cell function and lowered insulin requirements and serum CHGA levels for at least 2 years and these benefits were lost upon discontinuation. Thus, the current studies provide crucial mechanistic and clinical insight into the beneficial effects of verapamil in T1D.
multidisciplinary sciences
What problem does this paper attempt to address?